CA3064461A1 - Vaccine against necrotic enteritis in poultry - Google Patents

Vaccine against necrotic enteritis in poultry Download PDF

Info

Publication number
CA3064461A1
CA3064461A1 CA3064461A CA3064461A CA3064461A1 CA 3064461 A1 CA3064461 A1 CA 3064461A1 CA 3064461 A CA3064461 A CA 3064461A CA 3064461 A CA3064461 A CA 3064461A CA 3064461 A1 CA3064461 A1 CA 3064461A1
Authority
CA
Canada
Prior art keywords
polypeptide
pilus
seq
clostridium perfringens
poultry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3064461A
Other languages
English (en)
French (fr)
Inventor
Jianhua Gong
Dion LEPP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agriculture and Agri-Food Canada
Original Assignee
Agriculture and Agri-Food Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agriculture and Agri-Food Canada filed Critical Agriculture and Agri-Food Canada
Publication of CA3064461A1 publication Critical patent/CA3064461A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3064461A 2017-05-31 2018-05-31 Vaccine against necrotic enteritis in poultry Pending CA3064461A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513001P 2017-05-31 2017-05-31
US62/513,001 2017-05-31
PCT/CA2018/050643 WO2018218360A1 (en) 2017-05-31 2018-05-31 Vaccine against necrotic enteritis in poultry

Publications (1)

Publication Number Publication Date
CA3064461A1 true CA3064461A1 (en) 2018-12-06

Family

ID=64454163

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3064461A Pending CA3064461A1 (en) 2017-05-31 2018-05-31 Vaccine against necrotic enteritis in poultry

Country Status (8)

Country Link
US (2) US11318194B2 (enExample)
EP (1) EP3630800A4 (enExample)
JP (2) JP2020527051A (enExample)
CN (1) CN110691787A (enExample)
BR (1) BR112019025019A2 (enExample)
CA (1) CA3064461A1 (enExample)
MX (1) MX2019014450A (enExample)
WO (1) WO2018218360A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234130A (zh) * 2021-05-24 2021-08-10 安徽医科大学第四附属医院 一种卡氏肺孢子菌重组蛋白及其制备方法与应用
WO2025199604A1 (en) * 2024-03-27 2025-10-02 Université de Montréal Recombinant vaccine proteins for the prevention of avian necrotic enteritis
CN121759384B (zh) * 2026-03-05 2026-06-19 吉林农业大学 一种靶向树突状细胞的表达产气荚膜梭菌多抗原的重组乳杆菌及其构建方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) * 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
HK1045713A1 (zh) * 1999-07-13 2002-12-06 Medimmune, Inc. 供体链补体的菌毛蛋白和粘附素宽基疫苗
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
WO2007116322A2 (en) * 2006-02-17 2007-10-18 Novartis Ag Purification of bacterial antigens
US7745175B2 (en) * 2006-10-27 2010-06-29 Dow Agrosciences Llc Polynucleotides encoding Clostridium perfringens alpha toxin proteins
EP2086578B1 (en) * 2006-11-20 2012-01-11 Intervet International B.V. Use of clostridium perfringens type c bacterium for the manufacture of a vaccine
WO2008146164A2 (en) * 2007-05-25 2008-12-04 Novartis Ag Streptococcus pneumoniae pilus antigens
MX2009012924A (es) * 2007-06-08 2010-03-25 Australian Poultry Crc Pty Ltd Toxina clostridial netb.
US8501190B2 (en) * 2007-06-22 2013-08-06 The University Of Guelph Vaccine against Clostridium perfringens
WO2011113801A1 (en) * 2010-03-16 2011-09-22 Universiteit Gent Use of clostridium perfringens strain 23 to protect against necrotic enteritis
AR099470A1 (es) * 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
FR3065623B1 (fr) * 2017-04-28 2021-07-09 Roquette Freres Albumines de pois ameliorees, procede d'obtention et leurs applications
BR112021000100A2 (pt) * 2018-07-05 2021-03-30 Novobind Livestock Therapeutics Inc. Anticorpos contra agentes causadores de doença de aves domésticas e usos dos mesmos

Also Published As

Publication number Publication date
WO2018218360A1 (en) 2018-12-06
US11318194B2 (en) 2022-05-03
RU2019137515A (ru) 2021-06-30
JP2020527051A (ja) 2020-09-03
RU2019137515A3 (enExample) 2021-12-03
JP2023090702A (ja) 2023-06-29
CN110691787A (zh) 2020-01-14
MX2019014450A (es) 2020-02-10
BR112019025019A2 (pt) 2020-06-30
US20220226455A1 (en) 2022-07-21
EP3630800A1 (en) 2020-04-08
US20200093913A1 (en) 2020-03-26
EP3630800A4 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
US20220226455A1 (en) Vaccine against necrotic enteritis in poultry
Lenstra et al. Antigenicity of the peplomer protein of infectious bronchitis virus
Staczek et al. Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa
US20040087522A1 (en) Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic escherichia coli and other pathogens
CN103608464A (zh) 艰难梭菌抗原
JPH03184996A (ja) 大腸菌ワクチン
EP2532363B1 (en) Use of flagellins from the genus marinobacter as vaccination adjuvants
JP4160640B2 (ja) クラミジア・ニューモニエ由来の表面露出タンパク質
Seong et al. Mapping of antigenic determinant regions of the Bor56 protein of Orientia tsutsugamushi
EP1334197B1 (en) Yeast derived vaccine against ipnv
JP2009509496A (ja) ローソニアイントラセルラリスの免疫学的タンパク
CA2516661C (en) M. haemolytica outer membrane protein plpe as a vaccine or vaccine component against shipping fever
WO1998012331A1 (en) Novel polypeptide originating in hemophilus paragallinarum and process for producing the same
KR100563197B1 (ko) 개 파보바이러스 중화항원 결정기를 포함하는 ｖｐ2재조합 단백질 및 이를 포함하는 백신 조성물
RU2788096C2 (ru) Вакцина против некротического энтерита у домашней птицы
HK40019772A (en) Vaccine against necrotic enteritis in poultry
WO1988010298A1 (en) Ibdv vp2 epitope recognised by virus neutralising and protective monoclonal antibodies
Brant et al. Identification of linear antigenic sites on the Porphyromonas gingivalis 43‐kDa fimbrillin subunit
KR101242757B1 (ko) 개 코로나 바이러스 중화항원 결정기를 포함하는 스파이크재조합 단백질 및 이를 포함하는 백신 조성물
WO2008153339A2 (en) A vaccine for treating or preventing pasteurellosis using a yeast surface-expression system
US20010038844A1 (en) Methods and vaccines for protection against campylobacter infections
AU619477B2 (en) Ibdv vp2 epitope recognised by virus neutralising and protective monoclonal antibodies
JP4001117B2 (ja) ヘモフィルス・パラガリナラムａ型菌由来の感染防御抗原である組み換え蛋白
KR20120054465A (ko) 소 코로나바이러스 항원 결정기를 포함하는 스파이크 재조합 단백질 및 이에 대한 항체
EP1068229A1 (en) Peptides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230501

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240909

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251117

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260119